Immunoadsorption treatment for chronic inflammatory demyelinating polyneuropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, observational exploration enrolling about 140 adults with CIDP within the German Kompetenznetz Peripherer Nerv (KKPNS). Participants who are on or starting IVIg or methylprednisolone may be switched to immunoadsorption (IA) during an 18-month observation period if their response is insufficient. IA will be used as escalation therapy according to each center's therapeutic scheme, with a non-mandatory recommendation on session number, volumes, and frequency. Six-month follow-up visits and clinical outcome tracking will be used to collect safety and effectiveness information.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of CIDP based on the EAN/PNS Guidelines on Diagnosis and Treatment of CIDP13
* age ≥ 18 years
* Willing and capable of giving written informed consent
* Currently receiving IVIg or MP treatment OR starting IVIg or MP treatment at baseline

Exclusion Criteria:

* none

Where it's running

• University of Ulm
  Ulm, Baden-Wurttemberg, Germany Recruiting

Study contacts

• Principal investigator: Johannes Dorst — University of Ulm
• Study coordinator: Johannes Dorst, Prof. Dr.
• Email: johannes.dorst@uni-ulm.de
• Phone: +497311775285

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• KITE-363 treatment for relapsed or refractory autoimmune neurologic diseases

  This study will test whether KITE-363 is safe and can help people with relapsed or treatment-resistant autoimmune neurologic diseases such as MS, CIDP, and myasthenia gravis.

  Recruiting at 10 sites Phase 1 Gilead Sciences · Newport Beach, California and 9 other locations · NCT07304154

• Empasiprubart for adults with CIDP

  This study will test whether IV empasiprubart helps improve symptoms and is safe for adults with CIDP, with an initial 24-week randomized comparison to placebo followed by two years of empasiprubart for all participants.

  Recruiting at 94 sites Phase 3 argenx · Birmingham, Alabama and 93 other locations · NCT07091630

• Imeroprubart for adults with CIDP

  This study will test whether the monoclonal antibody Imeroprubart helps adults with active CIDP who are already on stable immunoglobulin or corticosteroid treatment.

  Recruiting at 117 sites Phase 2 Immunovant Sciences GmbH · Tucson, Arizona and 141 other locations · NCT07032662

• Empasiprubart versus IVIg for treating CIDP in adults

  This trial tests whether empasiprubart works as well as IVIg and is safe for adults with CIDP who currently benefit from IVIg.

  Recruiting at 107 sites Phase 3 argenx · Birmingham, Alabama and 106 other locations · NCT06920004

• Evaluating DNTH103 for treating chronic inflammatory demyelinating polyneuropathy

  This study is testing a new treatment called DNTH103 to see if it can help adults with chronic inflammatory demyelinating polyneuropathy feel better and stay safe.

  Recruiting at 201 sites Phase 3 Dianthus Therapeutics · Birmingham, Alabama and 200 other locations · NCT06858579

• KIg10 (intravenous human immune globulin 10%) maintenance therapy for CIDP

  This trial will test whether two different maintenance doses of IV immune globulin (KIg10), given every three weeks, help adults with CIDP stay stable and avoid worsening.

  Recruiting at 6 sites Phase 3 Kedrion S.p.A. · Stamford, Connecticut and 5 other locations · NCT06752356

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.